EPL Ltd Q4 FY26 Earnings Analysis

- EPL and Indovida together focus on emerging markets with significant growth potential; 90% of business will come from these underpenetrated markets. - EPL has delivered double-digit revenue growth for the last three consecutive quarters. - Indovida has achieved an 8% volume CAGR over the last five years, including organic and inorganic growth. - The combined entity maintains a guidance of double-digit revenue growth moving forward. - Indovida is expanding into new markets like Tanzania, Morocco, and Algeria, and more opportunities exist in Africa and Central Asia. - The merger enhances geographical footprint and customer base, adding new clients including Coca-Cola, Pepsi, ThaiBev, Masan, and Guinness. - Product and portfolio diversification, including closures and rigid plastic containers, presents additional growth avenues. - The combined entity is expected to leverage synergies to fuel growth through both organic expansion and future acquisitions.

- EPL continues to target double-digit revenue growth in the future, supported by a strong track record of consecutive quarterly growth. - Indovida has delivered an 8% volume CAGR over the past five years, including organic and inorganic expansion. - The combined entity expects significant growth opportunities as 90% of its business will be from emerging markets, which typically grow at twice the rate of developed markets. - The merger is expected to drive revenue synergies via geographical expansion and portfolio diversification, increasing customer base and market footprint. - EBITDA margins are anticipated to remain strong, supported by cost synergies, sourcing benefits, and supply chain optimizations. - Combined EBITDA is projected around INR1,750 crores with PAT of approximately INR815 crores. - The company aims to realize $35-$50 million in annual synergies post-merger, accelerating earnings growth. - Free cash flow conversion is healthy (60-65% of EBITDA), providing firepower for growth initiatives and M&A. - The long-term outlook is optimistic with a focus on margin accretive inorganic growth.

- The combined business sees significant opportunities for growth via both organic and inorganic routes. - Emphasis on inorganic growth includes acquisitions that expand geographical presence or build capabilities in new formats, provided they are margin accretive. - The merger creates a strong balance sheet with a debt-to-EBITDA ratio reducing to 0.25, providing firepower for growth and M&A. - Synergies from the merger valued at $35 million to $50 million annually will be realized through geographical expansion, portfolio diversification, and cost savings including procurement and supply chain optimization. - Long-term capex will focus on expanding footprint into new markets like India, Vietnam, Nigeria, and other emerging markets. - The company remains disciplined on capital allocation and will consider buybacks versus dividends depending on better opportunities. - Free cash flow conversion is healthy at about 60-65% of EBITDA, supporting continued investment in growth initiatives.

- Currently, there is no expectation to take on incremental debt post-merger as Indovida is net cash positive and debt-free. - The combined entity's debt-to-EBITDA ratio will decrease from 0.65 to 0.25, indicating a stronger balance sheet. - Cash flows are strong, with 60-65% of EBITDA converting to cash, providing firepower for growth opportunities. - Inorganic growth through acquisitions will continue but will be disciplined, focusing on margin-accretive and strategic opportunities. - Future dividend policy and capital allocation decisions will be made by the combined company's Board after merger completion. - No specific mention of immediate equity fundraising; emphasis is on leveraging free cash flow and balance sheet strength for growth. - The management is focused on organic and inorganic growth without increasing leverage.

The transcript provided from pages 1 to 19 of the EPL Limited conference call on March 30, 2026, does not mention any specifics regarding the current or expected order book or pending orders for EPL Limited or the merged entity with Indovida. The discussion primarily covers topics such as the merger rationale, valuation, synergy potentials, customer base, working capital, free cash flow, capital allocation, and market positioning, but there is no disclosure or commentary on order book status or pending orders. Therefore, no concrete information on current or expected order books or pending orders is available from the transcript provided.